HVO
+0.0 · +0.00%
GBX · LSE

hVIVO plc(HVO) Stock Analysis | Healthcare

GBX --+0.00%
Reward38Moderate
Risk77High
75%Data
Thin -12% profit margin · Revenue down 17% YoY
Earnings Deterioration
Market Cap:47.50M
ⓘ
Reward Rating
38
Moderate
Reward Assessment
75% data coverage
Bottom 5% of stocksView factors
ⓘ
Risk Rating
77
High
Risk Assessment
Risk factors availableUnlock details

Educational tool only – Scores are based on historical data and financial metrics for informational purposes. This is not financial advice or a recommendation to buy or sell any security. Always conduct your own research or consult a qualified financial adviser.

Educational tool only · More
Limited data coverage
We don't have enough public data on HVO to score it reliably yet — Reward, Risk, Forecasts and Dividends tabs aren't available for this stock. The price chart and basic profile are still shown.
OTC / ADR stock — scores and fundamentals use data tagged in USD by our provider. The issuer may report in a different home currency (e.g. JPY), so treat figures as directional rather than precise.
Not available yet for this stock
The overview tab requires data we don't have for this stock yet. The price chart is the most reliable view we have — try the Chart tab.
Earnings Ex-dividend

Market Performance

Stock returned +10.0% over the past year, broadly in line with market conditions.

What is hVIVO plc?

hVIVO plc operates as a full-service early specialist contract research organisation in the United Kingdom, Europe, and North America.

AI Brief Pro

The brief on hVIVO plc

The story behind the price, the case for and against, and what could go wrong. Open a part to read it.

What is hVIVO plc?

hVIVO plc operates as a full-service early specialist contract research organisation in the United Kingdom, Europe, and North America. It provides end-to-end early clinical development services to the biopharmaceutical industry, including phase I capabilities and world leading human challenge trial services. The company is listed on the LSE in UK, operating in the Healthcare sector, with a market capitalisation of 47.50M.

Financial Highlights

Investment Breakdown

Growth
Growth trend is developing — watch for revenue consistency over upcoming quarters.
Profitability
Thin or inconsistent margins weigh on earnings quality.
Risk
Elevated volatility implies higher downside and expectation risk.
Valuation
Valuation is less clear with a negative earnings base.

OpenBook Logo Analysis

Reward: Moderate (38)

Similar stocks to compare

A short list of Diagnostics & Research names that are close enough in size to make side-by-side comparison useful.

All Healthcare stocks →
Company Information
IndustryDiagnostics & Research
Beta1.694
Insider Activity
12M windowAwaiting coverage
LSE director-dealings coverage launching later this year. The data feed is in development.